LITAF Enhances Radiosensitivity of Human Glioma Cells Via the FoxO1 Pathway

Overview

Journal Cell Mol Neurobiol

Publisher Springer

Specialties Cell Biology
Molecular Biology
Neurology

Date 2019 May 18

PMID 31098771

Citations 13

Authors

Changlin Huang

Diangang Chen

Hongfan Zhu

Shengqing Lv

Qingrui Li

Guanghui Li

Affiliations

Soon will be listed here.

Abstract

Lipopolysaccharide-induced tumor necrosis factor alpha factor (LITAF), also called p53-induced gene 7 (PIG7), was identified as a transcription factor that activates transcription of proinflammatory cytokines in macrophages in response to lipopolysaccharide (LPS). Previous studies have identified LITAF as a potential tumor suppressor in several neoplasms, including prostate cancer, B-NHL, acute myeloid leukemia, and pancreatic cancer. However, the expression and function of LITAF in human glioma remain unexplained. The present study aimed to analyze the regulation of LITAF in gliomas. Data from The Cancer Genome Atlas (TCGA) database revealed that LITAF mRNA expression in glioma tissues was higher than that in normal brain tissues, and lower LITAF expression in gliomas showed a good prognosis in patients who received radiotherapy, by Kaplan-Meier analysis. In our collected specimens, however, LITAF showed low expression in glioma tissues compared to that in the normal brain tissue. Proliferation and apoptosis of glioma cells were not affected by knockdown or overexpression of LITAF in glioma U251, U373, and U87 cells, but LITAF was able to enhance the radiosensitivity of glioma cells. Furthermore, we found that LITAF enhanced radiosensitivity via FoxO1 and its specific downstream targets BIM, TRAIL, and FASLG. Taken together, our present results demonstrate that LITAF expression is decreased in glioma tissues and might enhance radiosensitivity of glioma cells via upregulation of the FoxO1 pathway.

Citing Articles

Homeobox B2 promotes malignant behavior and contributes to the radioresistance of nasopharyngeal carcinoma by regulating forkhead box protein O1.

Chen J, Mao M, Ma Z, Liu J, Jiang M, Chen G Int J Med Sci. 2024; 21(5):837-847.

PMID: 38617001 PMC: 11008478. DOI: 10.7150/ijms.93128.

Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics.

Tabnak P, Hasanzade Bashkandi A, Ebrahimnezhad M, Soleimani M Cancer Cell Int. 2023; 23(1):238.

PMID: 37821870 PMC: 10568859. DOI: 10.1186/s12935-023-03090-7.

Identification of T-cell exhaustion-related gene signature for predicting prognosis in glioblastoma multiforme.

Liu Y, Jin H, Liu H J Cell Mol Med. 2023; 27(22):3503-3513.

PMID: 37635346 PMC: 10660619. DOI: 10.1111/jcmm.17927.

LITAF inhibits colorectal cancer stemness and metastatic behavior by regulating FOXO1-mediated SIRT1 expression.

Guan J, Zhang Z, Sun J, Wang X, Zhou Z, Qin L Clin Exp Metastasis. 2023; 40(4):309-320.

PMID: 37266842 DOI: 10.1007/s10585-023-10213-x.

Enhances Nasopharyngeal Carcinoma Cell Radiosensitivity the //Signal Transducer and Activator of Transcription-1/Forkhead Box O-1 Axis.

Deng L, Yin Q, Liu S, Luo D Dis Markers. 2022; 2022:5699275.

PMID: 36061358 PMC: 9439912. DOI: 10.1155/2022/5699275.

References

Kayal R, Siqueira M, Alblowi J, McLean J, Krothapalli N, Faibish D . TNF-alpha mediates diabetes-enhanced chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis through FOXO1. J Bone Miner Res. 2010; 25(7):1604-15. PMC: 3154002. DOI: 10.1002/jbmr.59. View

Zhao M, Luo R, Liu Y, Gao L, Fu Z, Fu Q . miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. Nat Commun. 2016; 7:11309. PMC: 4842991. DOI: 10.1038/ncomms11309. View

Merrill J, You J, Constable C, Leeman S, Amar S . Whole-body deletion of LPS-induced TNF-α factor (LITAF) markedly improves experimental endotoxic shock and inflammatory arthritis. Proc Natl Acad Sci U S A. 2011; 108(52):21247-52. PMC: 3248491. DOI: 10.1073/pnas.1111492108. View

Ito Y, Daitoku H, Fukamizu A . Foxo1 increases pro-inflammatory gene expression by inducing C/EBPbeta in TNF-alpha-treated adipocytes. Biochem Biophys Res Commun. 2008; 378(2):290-5. DOI: 10.1016/j.bbrc.2008.11.043. View

Bois P, Izeradjene K, Houghton P, Cleveland J, Houghton J, Grosveld G . FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol. 2005; 170(6):903-12. PMC: 2171446. DOI: 10.1083/jcb.200501040. View

Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama J . Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res. 2011; 2(1):104-15. PMC: 3236574. View

Zhou Y, Huang J, Yu X, Jiang X, Shi Y, Weng Y . is a potential tumor suppressor in pancreatic cancer. Oncotarget. 2018; 9(3):3131-3142. PMC: 5790452. DOI: 10.18632/oncotarget.23220. View

Agnihotri S, Burrell K, Wolf A, Jalali S, Hawkins C, Rutka J . Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz). 2012; 61(1):25-41. DOI: 10.1007/s00005-012-0203-0. View

Hoey C, Ray J, Jeon J, Huang X, Taeb S, Ylanko J . miRNA-106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation. Mol Oncol. 2018; 12(8):1324-1341. PMC: 6068351. DOI: 10.1002/1878-0261.12328. View

10.

Xie L, Ushmorov A, Leithauser F, Guan H, Steidl C, Farbinger J . FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012; 119(15):3503-11. DOI: 10.1182/blood-2011-09-381905. View

11.

Schijns V, Pretto C, Strik A, Gloudemans-Rijkers R, Deviller L, Pierre D . Therapeutic Immunization against Glioblastoma. Int J Mol Sci. 2018; 19(9). PMC: 6163986. DOI: 10.3390/ijms19092540. View

12.

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

13.

Wang X, Yu Y, Gu L . Dehydroabietic acid reverses TNF-α-induced the activation of FOXO1 and suppression of TGF-β1/Smad signaling in human adult dermal fibroblasts. Int J Clin Exp Pathol. 2015; 7(12):8616-26. PMC: 4314026. View

14.

Zhang Y, Gan B, Liu D, Paik J . FoxO family members in cancer. Cancer Biol Ther. 2011; 12(4):253-9. DOI: 10.4161/cbt.12.4.15954. View

15.

LaPointe S, Perry A, Butowski N . Primary brain tumours in adults. Lancet. 2018; 392(10145):432-446. DOI: 10.1016/S0140-6736(18)30990-5. View

16.

Wesseling P, Capper D . WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2017; 44(2):139-150. DOI: 10.1111/nan.12432. View

17.

Gilley J, Coffer P, Ham J . FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol. 2003; 162(4):613-22. PMC: 2173804. DOI: 10.1083/jcb.200303026. View

18.

Mestre-Escorihuela C, Rubio-Moscardo F, Richter J, Siebert R, Climent J, Fresquet V . Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood. 2006; 109(1):271-80. DOI: 10.1182/blood-2006-06-026500. View

19.

Wang J, Shi Y, Wang L, Ren G, Bai Y, Shi H . [Significance of expression and promoter methylation of LITAF gene in B-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi. 2014; 43(8):516-21. View

20.

Ostrom Q, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C . CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017; 19(suppl_5):v1-v88. PMC: 5693142. DOI: 10.1093/neuonc/nox158. View